Table of Contents
ISRN Oncology
Volume 2011, Article ID 585192, 6 pages
http://dx.doi.org/10.5402/2011/585192
Research Article

Use of Pattern Recognition Analysis to Identify Underlying Relationships of Doxorubicin Derivatives Optimized for Breast Cancer Treatment

Chemistry Department, Durham Science Center, University of Nebraska at Omaha, 6001 Dodge Street, Omaha, NE 68182, USA

Received 17 April 2011; Accepted 11 May 2011

Academic Editors: A. E. Bilsland and G. Schiavon

Copyright © 2011 Ronald Bartzatt. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. R. B. Weiss, “The anthracyclines: will we ever find a better doxorubicin?” Seminars in Oncology, vol. 19, no. 6, pp. 670–686, 1992. View at Google Scholar · View at Scopus
  2. G. Minotti, P. Menna, E. Salvatorelli, G. Cairo, and L. Gianni, “Anthracyclines: molecular advances and pharmacologie developments in antitumor activity and cardiotoxicity,” Pharmacological Reviews, vol. 56, no. 2, pp. 185–229, 2004. View at Publisher · View at Google Scholar · View at Scopus
  3. C. H. Takimoto and E. Calvo, “Principles of oncologic pharmacotherapy,” in Cancer Management: A Multidisciplinary Approach, R. Pazdur, L. D. Wagman, K. A. Camphausen, and W. J. Hoskins, Eds., pp. 42–58, UBM Medica, London, UK, 2008. View at Google Scholar
  4. X. Peng, B. Chen, C. C. Lim, and D. B. Sawyer, “The cardiotoxicology of anthracycline chemotherapeutics: translating molecular mechanism into preventative medicine,” Molecular Interventions, vol. 5, no. 3, pp. 163–171, 2005. View at Publisher · View at Google Scholar · View at Scopus
  5. L. C. M. Kremer, E. C. van Dalen, M. Offringa, J. Ottenkamp, and P. A. Voûte, “Anthracycline-induced clinical heart failure in a cohort of 607 children: long-term follow-up study,” Journal of Clinical Oncology, vol. 19, no. 1, pp. 191–196, 2001. View at Google Scholar · View at Scopus
  6. E. van Dalen, H. N. Caron, H. O. Dickinson, and L. C. M. Kremer, “Cardioprotective interventions for cancer patients receiving anthracyclines,” Cochrane Database of Systematic Reviews, no. 2, Article ID CD003917, 2008. View at Publisher · View at Google Scholar · View at Scopus
  7. P. Dombernowsky, J. Gehl, M. Boesgaard, T. P. Jensen, B. W. Jensen, and B. Ejlertsen, “Treatment of metastatic breast cancer with paclitaxel and doxorubicin,” Seminars in Oncology, vol. 22, no. 6, supplement 15, pp. 13–17, 1995. View at Google Scholar · View at Scopus
  8. F. A. Holmes, V. Valero, R. S. Walters et al., “Paclitaxel by 24-hour infusion with doxorubicin by 48-hour infusion as initial therapy for metastatic breast cancer: pharm results,” Annals of Oncology, vol. 10, no. 4, pp. 403–411, 1999. View at Google Scholar
  9. N. Colombo, G. Parma, L. Bocciolone, D. Franchi, M. Sideri, and A. Maggioni, “Medical therapy of advanced malignant epithelial tumours of the ovary,” FORUM, vol. 10, no. 4, pp. 323–332, 2000. View at Google Scholar · View at Scopus
  10. D. Mavroudis, C. Kouroussis, S. Kakolyris et al., “Phase I study of paclitaxel (Taxol) and pegylated liposomal doxorubicin (Caelyx) administered every 2 weeks in patients with advanced solid tumors,” Oncology, vol. 62, no. 3, pp. 216–222, 2002. View at Publisher · View at Google Scholar · View at Scopus
  11. D. Bafaloukos, H. Linardou, G. Aravantinos et al., “A randomized phase II study of carboplatin plus pegylated liposomal doxorubicin versus carboplatin plus paclitaxel in platinum sensitive ovarian cancer patients: a Hellenic Cooperative Oncology Group study,” BMC Medicine, vol. 8, no. 1, article 3, 2010. View at Publisher · View at Google Scholar
  12. C. A. Lipinski, F. Lombardo, B. W. Dominy, and P. J. Feeney, “Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings,” Advanced Drug Delivery Reviews, vol. 46, no. 1–3, pp. 3–26, 2001. View at Publisher · View at Google Scholar · View at Scopus
  13. G. Thomas, Medicinal Chemistry: An Introduction, John Wiley & Sons, New York, NY, USA, 2008.
  14. A. Leo, C. Hansch, and D. Elkins, “Partition coefficients and their uses,” Chemical Reviews, vol. 71, no. 6, pp. 525–616, 1971. View at Google Scholar · View at Scopus
  15. S. T. Bow, Pattern Recognition, Marcel Dekker, New York, NY, USA, 1984.
  16. N. Saitou and M. Nei, “The neighbor-joining method: a new method for reconstructing phylogenetic trees,” Molecular biology and evolution, vol. 4, no. 4, pp. 406–425, 1987. View at Google Scholar · View at Scopus
  17. A. Suarato, F. Angelucci, A. Bargioti et al., Synthesis and study of structure-activity relationships of new classes of anthracyclines, ACS Publications, Washington, DC, USA, 1994.
  18. D. H. Altreuter, J. S. Dordick, and D. S. Clark, “Nonaqueous biocatalytic synthesis of new cytotoxic doxorubicin derivatives: exploiting unexpected differences in the regioselectivity of salt-activated and solubilized subtilisin,” Journal of the American Chemical Society, vol. 124, no. 9, pp. 1871–1876, 2002. View at Publisher · View at Google Scholar · View at Scopus